“We have not been approached by anybody that has an offer that would make those scenarios attractive, but we continually look for ways of increasing shareholder value and are open to any of those ideas,” Pfizer (PFE +3.2%) CEO Ian Read tells Bloomberg post-earnings, responding to a question about a split of the company or interest in its products line from generic drugmakers. The stock’s ahead today as results were boosted by a big drop in the stock float, a cut in operating expenses, and a two percentage point drop in the tax rate, but has badly lagged the broad pharmaceutical sector over the last year.
Help employers find you! Check out all the jobs and post your resume.
